AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?

AbbVie, a pharmaceutical company renowned for its work in immunology, has found success in recent years through its migraine franchise. AbbVie's chief growth driver has been Humira, a drug for autoimmune disorders that once held the title of the world's best-seller. However, AbbVie now has other products in other areas that are also performing well, including the migraine treatment Qulipta.

Qulipta recently achieved a significant clinical win in a Phase 3 trial for menstrual migraine prevention. This trial's top-line results showed a meaningful reduction in migraine days compared to a placebo during the perimenstrual period, leading to a potential label expansion for this indication. With no other medicines approved specifically for menstrual migraine, the total market opportunity for Qulipta in this niche could exceed nine million adult patients in the U.S. Although Qulipta will not reach 100% market penetration, its impact on Qulipta's performance should be substantial.

The company's Skyrizi and Rinvoq are expected to remain its primary growth drivers, with AbbVie predicting over $31 billion in combined revenue for these drugs this year. AbbVie's immunology portfolio is also set to expand with the recent acquisition of Apogee Therapeutics, which includes a promising immunology asset called zumilokibart.

This asset could generate peak sales of $5.2 billion in eczema alone, potentially becoming one of AbbVie's future growth pillars. AbbVie is a Dividend King, having increased its dividends for 50 consecutive years, making it an attractive stock for income-seeking investors. Despite some analysts not recommending AbbVie as part of their top 10 list, its consistent financial performance, promising pipeline, and dividend growth make it a strong buy and hold option for long-term investors.